Where does stocks-llm's data on EOLS come from?

Fundamentals and prices come from Finnhub, as of 2026-07-10; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.

← stocks-llm Find companies like EOLS →

EVOLUS INC (EOLS)

Health Care · Medical aesthetics injectables · NASDAQ

A global performance beauty company specializing in injectable aesthetic products, primarily botulinum toxin (Jeuveau®) and hyaluronic acid gels (Evolysse™), for the direct-pay medical aesthetics market.

View SEC filings Website Yahoo Finance Find companies like EOLS → Ask about EOLS →

What EVOLUS INC does

Evolus is a global performance beauty company focused on the cash-pay aesthetic market, delivering injectable products to aesthetic practitioners. The company's primary commercial product is Jeuveau® (prabotulinumtoxinA-xvfs), a botulinum toxin type A formulation for temporary improvement of frown lines, and Evolysse™, a collection of injectable hyaluronic acid gels for treatment of wrinkles and folds including nasolabial folds, mid-face volume, lip fullness, and infraorbital hollow correction. Products are marketed in the United States, Canada, Europe, and Australia, with Evolysse™ Sculpt and Evolysse™ Lips pending FDA approval anticipated in 2026-2027.

Themes: ["Injectable botulinum toxin / neurotoxins","Injectable dermal fillers / hyaluronic acid gels","Medical aesthetics / cosmetic injectables","Cash-pay aesthetic market","Direct-to-practitioner distribution"]

Fundamentals

Price$6.85 as of 2026-07-09 close
Market cap$448M as of 2026-07-10
1-year return-29.1% as of 2026-07-09 close
Net margin-14.4% as of 2026-07-10
Gross margin+66.1% as of 2026-07-10
ROE-410.2% as of 2026-07-10
Debt / equity22.00 as of 2026-07-10
Revenue growth (YoY)+9.6% as of 2026-07-10
Revenue CAGR (3y)+26.0% SEC XBRL
Beta1.38 as of 2026-07-10

Ask why EOLS looks like this →

Key risks (from latest filing)

["Tariff exposure: Jeuveau® is manufactured and imported from South Korea; April 2026 White House proclamation authorizes tariffs on certain pharmaceutical imports from South Korea, with uncertain timing and scope, potentially impacting product costs and margins.","Consumer discretionary sensitivity: Lower consumer confidence and weakening discretionary spending due to inflation, tariffs, and economic volatility have negatively impacted aesthetic procedure demand and future sales.","Market competition: BOTOX (onabotulinumtoxinA) dominates the neurotoxin market, and the company faces competition from multiple established injectable filler manufacturers in the hyaluronic acid gel segment."]

See EOLS's biggest risks from its latest 10-Q →

Competitors & peers

BOTOX (Allergan/AbbVie)
Dysport (Galderma)
Xeomin (Merz)
Restylane (Galderma)
Juvéderm (Allergan/AbbVie)
Radiesse (Merz)

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.